Pharmaceuticals Europe: Approval to Access Gap
Decision brief
Answer first · skim in under a minute
Despite EMA approvals, patients across Europe face delayed or no access to new medicines. This analysis examines the systemic barriers, the EU Pharma Package response, and the strategic implications for European pharma companies and investors.
Pharmaceuticals Europe still separates EMA authorisation from day-one patient access. The EU HTA Regulation now runs joint clinical assessments, but national pricing and reimbursement decide whether an approved medicine actually reaches patients.
Contents11 sections
Key Takeaways
- EMA centralized authorisation is EU-wide; access still depends on national HTA and pricing.
- Regulation (EU) 2021/2282 applies from 12 January 2025, starting with oncology and ATMPs.
- Commission Q&A targets JCA completion within about 30 days after authorisation for covered products.
- Orphan medicines join in January 2028; all new centralised medicines by 2030 under the staged plan.
Why does pharmaceuticals Europe still show an approval-to-access gap?
EMA can grant a marketing authorisation valid across EU member states through the centralized procedure. That decision answers quality, safety, and efficacy for EU use.
Access is different. Each country still runs health technology assessment, pricing, and reimbursement steps. Those national layers create the delay between label and patient.
EMA context: EMA authorisation of medicines.
What does the EU HTA Regulation change in 2025–2030?
Regulation (EU) 2021/2282 creates permanent EU cooperation on health technology assessment. It entered into force in January 2022 and applies from 12 January 2025.
Joint clinical assessments begin with new cancer medicines and advanced therapy medicinal products. Selected high-risk medical devices follow from 2026. Orphan medicines are scheduled for January 2028, with all new medicinal products covered by 2030.
Legal text: Regulation (EU) 2021/2282 on EUR-Lex.
How fast are joint clinical assessments supposed to run?
Commission materials say joint clinical assessments of new cancer medicines and ATMPs are to be completed within 30 days after the medicine is authorised. The goal is to cut duplicated national clinical assessments that can lag years behind approval.
Member States still use JCA reports in their own decisions on system inclusion. A faster clinical assessment does not by itself set a price or reimbursement date.
Commission overview: EU HTA Regulation overview.
What early 2026 JCA examples show about implementation?
In June 2026, the Commission published joint clinical assessment reports for tarlatamab (Imdylltra) and lurbinectedin (Zepzelca) in extensive-stage small cell lung cancer.
Those reports were endorsed by Member States on 22 June 2026 after Commission marketing authorisation on 29 May 2026. The sequence shows JCA operating as a shared clinical evidence product after authorisation, not as a substitute for national access deals.
Commission note: Commission publishes JCA reports on two lung cancer medicines.
How should BD teams prepare evidence packages?
Developers should plan for a single EU-level clinical evidence submission used in joint work, then tailor national economic and budget models separately. Oncology and ATMP assets in the 2025–2027 window are first in line.
Track whether major markets integrate JCA outputs into pricing clocks. If Germany, France, and Italy treat JCA as the clinical baseline, launch sequencing for pharmaceuticals Europe can compress. If not, duplication risk remains.
What industry access metrics still matter?
EFPIA’s Patients W.A.I.T. Indicator remains a widely cited industry dataset on time from marketing authorisation to availability across Europe. Use it as a comparative access pulse, not as an official EU statistic.
Pair W.A.I.T. tables with Commission HTA trackers and EMA authorisation dates when briefing boards. That triangulation shows whether policy tools are moving national clocks.
Industry report: EFPIA Patients W.A.I.T. Indicator (PDF).
What remains unproven about “closing the gap”
HTA Regulation application does not guarantee equal launch timing across all 27 member states. Pricing negotiations, budget caps, and managed-entry agreements can still stretch years.
EU Pharma Package talks continue to evolve. Do not treat draft data-protection incentives as final law until the adopted text is published in the Official Journal.
For 2026 planning, keep a living tracker that pairs each EMA authorisation date with JCA publication status and first national reimbursement decision in your top five EU markets.
Related NovaPharma coverage
- EFPIA Patients W.A.I.T. Indicator 2025
- EMA approved 104 human medicines in 2025
- EMA 2025 Annual Report annexes
Frequently Asked Questions
What is the process of drug approval in Europe?
EMA’s centralized procedure can grant a single marketing authorisation valid across EU member states. National HTA, pricing, and reimbursement decisions still determine when patients can access the medicine.
When did the EU HTA Regulation start to apply?
Regulation (EU) 2021/2282 entered into force in January 2022 and has applied since 12 January 2025, starting with joint clinical assessments for new cancer medicines and ATMPs.
Does a joint clinical assessment guarantee reimbursement?
No. Joint clinical assessment reports support Member State decision-making. Pricing and reimbursement remain national, so access timing can still diverge after EU-level clinical assessment.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
